AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson

UnitedHealth Group

In addition to favorable price action, all three carry a strong growth profile, making them appear even more enticing.

3 Medical Stocks Displaying Remarkable Relative Strength in 2022

Ionis Pharma

Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing. The post Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test appeared first on Investor's Business Daily.

Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test

Ultomiris, the generalised myasthenia gravis (gMG) treatment developed by multinational pharmaceutical giant AstraZeneca PLC (LSE:AZN), has been approved for adult treatment in Europe. The nod from the European Commission marks the first and only approval for a long-acting C5 complement inhibitor for the treatment of the debilitating autoimmune disease.

AstraZeneca wins European approval for Ultomiris autoimmune disease treatment

AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.

AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe

AstraZeneca PLC (LSE:AZN) said a drug it has developed jointly with Merck has been approved for use in women with advanced ovarian cancer by the Chinese authorities. Lynparza has been signed off as a maintenance treatment for a sub-group of women that have the HRD-positive form of the disease.

AstraZeneca receives China green light for Lynparza

Following the label expansion approval in the European Union, Evusheld is currently the only long-acting antibody combination available for both prevention and treatment of COVID-19.

AstraZeneca (AZN) Gets EU Nod for Evusheld to Treat COVID

Adobe

Don't let the bear market scare you into thinking these solid companies have become bad investments.

Got $5,000? These 2 Growth Stocks Are Near Their 52-Week Lows

AstraZeneca PLC (LSE:AZN) said its long-acting antibody combination Evusheld (tixagevimab and cilgavimab, formerly AZD7442) has been approved in the EU for the treatment of Covid-19.  The approval by the European Commission covers people over the age of 12 years who do not require supplemental oxygen and who are at increased risk of progressing to severe Covid‑19, the pharmaceuticals group said in a statement.

AstraZeneca's Evusheld approved for treatment of Covid-19 in EU

CHMP recommends authorizing AstraZeneca's (AZN) Evusheld as a COVID-19 treatment and its RSV vaccine, nirsevimab in Europe.

AstraZeneca (AZN) Gets CHMP Nod for Evusheld to Treat COVID

AbbVie

Merck

Novartis

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.

4 Large Drug Stocks to Watch as Fundamentals Stay Strong

AstraZeneca PLC (LSE:AZN) shares were among the top risers on the FTSE 100 after it received a triple dose of good news, including backing from the European Union drug regulator for its Covid-19 treatment. Evusheld, a long-acting antibody combination, has been recommended for approval in the EU for those older than 12 years with Covid who do not require supplemental oxygen and who are at increased risk of progressing to severe form of the disease.

AstraZeneca gets EU backing for Covid-19 treatment and RSV drug

WILMINGTON, Del.--(BUSINESS WIRE)--Today, AstraZeneca (Nasdaq: AZN) launched Up The Antibodies, an important new campaign that embraces the reality for millions of immunocompromised Americans1,2: COVID-19 isn't over. While it feels like life has gone back to normal for many, this community still has very real cause for concern. Now, an added layer of COVID-19 protection can help people who are immunocompromised start to get back out into the world, doing what they love with whom they love. A re

AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19

Eli Lilly

Roche Holding AG

Shares in pharmaceutical giants including Roche, Novo Nordisk, Eli Lilly and AstraZeneca were little changed Wednesday despite getting a ratings boost from analysts at Berenberg, who cited respective returns on research and development investment and the ability of those companies to withstand pressure coming from recent U.S drug price reform.

AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer

ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer

Microsoft

The stocks are profitable, stable, and pay dividends.

Got $5,000? These 2 Stocks Are No-Brainer Buys.

BOSTON--(BUSINESS WIRE)--Gatehouse Bio, a pioneer in small RNA therapeutics, and AstraZeneca, a global, science-led biopharmaceutical company, are advancing their partnership, to create RNA therapeutics for the treatment of heart failure with preserved ejection fraction (HFpEF). HFpEF is a heterogenous condition complicated by multiple interrelated diseases. In a prior study, Gatehouse Bio discovered mutations in small RNA genes that correlate to microvascular dysfunction and were predicted to

Gatehouse Bio Extends Its Partnership with AstraZeneca to Develop RNA Therapeutics for Heart Failure

AstraZeneca's (AZN) Imfinzi plus chemotherapy becomes the first immunotherapy combination to get approval in the United States to treat advanced biliary tract cancer

AstraZeneca (AZN) Imfinzi Gets FDA Nod for Biliary Tract Cancer

AstraZeneca's stock dipped 5.8% in August, the biggest monthly fall in 2022, raising the question whether it is a good time to buy the otherwise high-performing stock on dip. Factors like relatively better performance by healthcare stocks in the current sluggish economy and markets, the company's geographical diversification, strong pricing power, and healthy financials work in its favor.

AstraZeneca: Buy On The Dip

GlaxoSmithKline

AstraZeneca PLC (LSE:AZN) has succeeded in stopping a former senior executive from joining rival GSK PLC (LSE:GSK, NYSE:GSK) via an injunction granted by a High Court judge.  Having recently left AstraZeneca after holding several senior positions, Chris Sheldon was due to join GSK on September 1, in charge of developing the group's therapy businesses.

AstraZeneca wins injunction preventing former executive from joining GSK

AstraZeneca's (AZN) Evusheld gets approval in Japan for treating COVID-19. This is the first global approval for Evusheld as a COVID-19 treatment.

AstraZeneca (AZN) Evusheld Gets Japan Nod as COVID Treatment

Pfizer

The U.S. government expects its supply of COVID-19 vaccines and antiviral treatments to run out over the next year and is preparing for them to be sold via the commercial market, the Department of Health and Human Services said on Tuesday.

U.S. plans to move COVID vaccines, treatments to private markets in 2023

A diabetes drug developed by AstraZeneca PLC (LSE:AZN) has shown great promise in treating people with heart failure. The use of Farxiga led to ‘significantly lower risks' of hospitalisation and death, investors were told.

AstraZeneca successfully used to treat heart failure

The Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca's (AZN) three marketed drugs, Lynparza, Tagrisso and Ultomiris, for three different indications in Japan.

AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs

Thai drugmaker Siam Bioscience, owned by the country's king, reported a near 50-fold increase in annual profit in 2021, when it began producing AstraZeneca Plc's COVID-19 vaccine, government data shows.

Thai king's medical firm reports record profit after vaccine deal with AstraZeneca

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present new data supporting its ambition to redefine cancer care at the European Society for Medical Oncology (ESMO) Congress 2022, September 9 – 13, 2022. A total of 15 approved and potential new medicines from AstraZeneca will be featured across more than 75 abstracts in 13 tumor types. Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “At ESMO this year, new evidence will demonstrate how our medicines ar

News for AstraZeneca Stock (AZN)